EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study

Louisa G Kluijver, Mitra Nekouei Shahraki, Margreet A E M Wagenmakers, Bettina E Hanssen, Viola Kuerten, Kathrin Schelonke, Bernhard Homey, Janneke G Langendonk

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae148 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Louisa G Kluijver und 7 weiteren Autor:innen. Beteiligte Einrichtung: Porphyria Centre Rotterdam, Centre for Lysosomal and Metabolic Disease, Department of Internal Medicine, Erasmus MC, Erasmus University Medical Centr…. Hauptthemen laut MEDLINE: Vitamin D Deficiency, Cholecalciferol, Protoporphyria, Erythropoietic, Vitamin D. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erasmus MC, Alnylam, Clinuvel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with erythropoietic protoporphyria experience lifelong painful photosensitivity resulting in a lack of sunlight exposure. Previous studies have shown that 47–63% of patients with EPP suffer from vitamin D deficiency and a high prevalence of osteoporosis. An effective treatment for EPP has been available since 2016: the α-melanocyte stimulating hormone analogue afamelanotide. So far, studies on vitamin D levels in EPP have only investigated patients who have not been treated with afamelanotide.

Objectives

To investigate the effects of afamelanotide treatment on vitamin D levels in EPP.

Methods

A multicentre observational cohort study in adults with EPP from the Erasmus Medical Centre, the Netherlands, and the University Hospital Düsseldorf, Germany, was carried out. Routinely collected vitamin D levels between 2005 and 2021 were used for analysis. Patient exposure to cholecalciferol or afamelanotide was categorized into four treatment groups: untreated, cholecalciferol, afamelanotide and combined treatment. A linear mixed model for longitudinal data was applied to measure the effect of the treatment groups compared with the untreated groups on vitamin D levels.

Results

A total of 230 patients and 1774 vitamin D measurements were included. The prevalence of vitamin D deficiency and severe deficiency remained high despite afamelanotide treatment (< 50 nmol L–1 in 71.8% of patients and < 30 nmol L–1 in 48.1%, respectively). Afamelanotide treatment alone did not lead to a significant average increase in vitamin D levels [β = 0.5, 95% confidence interval (CI) –3.2 to 4.2]. In contrast, cholecalciferol and combined therapy with afamelanotide led to a significant increase in vitamin D levels [β = 11.6 (95% CI 7.2–15.9) and β = 15.2 (95% CI 12.3–18.1), respectively].

Conclusions

Cholecalciferol remains essential for the treatment of vitamin D deficiency in EPP, irrespective of new treatment options like afamelanotide. Afamelanotide treatment did not affect vitamin D levels. We suggest that future guidelines include continuous monitoring of vitamin D and a prescription for cholecalciferol in all patients with EPP, including those treated with afamelanotide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitamin D DeficiencyCholecalciferolProtoporphyria, ErythropoieticVitamin DHumansMaleFemaleMiddle AgedAdultalpha-MSHTreatment OutcomeAgedDrug Therapy, Combination

Substanzen

CholecalciferolafamelanotideVitamin Dalpha-MSH

Autor:innen und Institutionen

  • Porphyria Centre Rotterdam, Centre for Lysosomal and Metabolic Disease, Department of Internal Medicine, Erasmus MC, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Department of Epidemiology, Biostatistics, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands.
  • Department of Dermatology, University Hospital Düsseldorf, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.

Förderung

  • Erasmus MC
  • Alnylam
  • Clinuvel
  • Ultragenyx

Zitieren

APA

Kluijver, L. G., Nekouei Shahraki, M., Wagenmakers, M. A. E. M., Hanssen, B. E., Kuerten, V., Schelonke, K., Homey, B., & Langendonk, J. G. (2024). The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae148

Vancouver

Kluijver LG, Nekouei Shahraki M, Wagenmakers MAEM, Hanssen BE, Kuerten V, Schelonke K, et al. The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae148

BibTeX
@article{Kluijver2024,
  author = {Kluijver, Louisa G and Nekouei Shahraki, Mitra and Wagenmakers, Margreet A E M and Hanssen, Bettina E and Kuerten, Viola and Schelonke, Kathrin and Homey, Bernhard and Langendonk, Janneke G},
  title = {The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae148}
}
Kostenlos starten →